Abstract
Aim: To compare the potential amelioration of dyslipidemia and LDL particle size by alogliptin and voglibose in patients with impaired glucose tolerance (IGT) or Type 2 diabetes mellitus (T2DM). Patients & methods: Patients (n = 37; 25 patients with IGT and 12 patients with newly diagnosed T2DM) were randomly assigned to treatment with either alogliptin (25 mg daily for 12 weeks) or voglibose (0.6 mg daily for 12 weeks). A 75-g oral glucose tolerance test and laboratory measurements were performed at baseline and after treatment. LDL particle size was evaluated by electrophoresis of lipoproteins. Results: Following treatment, alogliptin, but not voglibose, decreased triglycerides (p < 0.01) and increased HDL cholesterol (p < 0.05), and significantly decreased the relative mobility value (p < 0.05). Conclusion: Alogliptin ameliorates dyslipidemia and increases LDL particle size in patients with IGT or T2DM.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
